Categories Earnings, Health Care

Biogen (NASDAQ: BIIB): Q4 2019 Earnings Snapshot

— Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter 2019 adjusted earnings of $8.34 per share versus $8.02 per share expected.

— Total revenues increased by 4% to $3.67 billion versus $3.54 billion expected.

Biogen (BIIB) Q4 2019 Earnings Snapshot

— Total product revenues rose by 4% driven by growth in multiple sclerosis drugs, spinal muscular atrophy drug Spinraza, biosimilars Benepali, Imraldi, and Flixabi.

— Research and development expense rose by 13% due to the inclusion of charges related to Samsung Bioepis transaction, related to the option exercise with Ionis Pharmaceuticals, and related to collaboration agreements with CAMP24 Therapeutics and Catalyst Biosciences.

— Looking ahead into the full year 2020, the company expects revenue in the range of $14-14.3 billion and adjusted earnings in the range of $31.50-33.50 per share. Analysts expect EPS of $33.03 on revenue of $14.06 billion.

— The earnings are anticipated to be in the range of $29.50-31.50 per share for the full year.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.

Most Popular

What to expect when Signet Jewelers (SIG) reports Q1 earnings

Shares of Signet Jewelers Limited (NYSE: SIG) were over 3% on Monday. The stock has dropped 13% over the past 3 months. The jewelry retailer is set to report its

MDB Infographic: Highlights of MongoDB’s Q1 2024 earnings report

Software company MongoDB, Inc. (NASDAQ: MDB) has announced financial results for the first quarter of 2024, posting an increase in revenues and adjusted profit. The company reported a 29% increase

Campbell Soup to report Q3 results Wednesday. Here’s what to expect

Campbell Soup Company (NYSE: CPB) is coming out of a rough patch after the packaged food company's sales and earnings got affected by the pandemic, due to the widespread movement

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top